Abstract

 Limited evidence from 1 cost-consequence analysis study showed that eltrombopag was the preferred thrombopoietin receptor agonist over romiplostim (i.e., less expensive and more effective) for treatment of chronic immune thrombocytopenia in pediatric patients.
 No cost-effectiveness studies of dapsone or rituximab were identified.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
